Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Glaucoma, Open-Angle, Chronic Wounds
Interventions: Timolol Maleate; Drug
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mather, California

Conditions: Glaucoma, Open-Angle
Interventions: OMNI canaloplasty, Hydrus microstent; Device
Lead sponsor: Ridge Eye Care; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Marysville, California • Oroville, California • Paradise, California + 1 more

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more

Conditions: Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1976 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Wichita, Kansas • Bloomington, Minnesota + 7 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Narrow Angle, Open Angle
Interventions: ANTERION; Device
Lead sponsor: Heidelberg Engineering GmbH; Industry
Eligibility: 22 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Glaucoma, Open-Angle
Interventions: Hydrus Microstent, Incisional goniotomy, Excisional goniotomy; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: MINIject™ Implant; Device
Lead sponsor: iSTAR Medical; Industry
Eligibility: 46 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 28
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more

Conditions: Glaucoma
Interventions: Latanoprost, Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669, bimatoprost, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glaucoma Open-angle
Interventions: Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Open Angle Glaucoma
Interventions: Nasal 180° Selective Laser Trabeculoplasty (SLT), Inferior 180° Selective Laser Trabeculoplasty (SLT); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma and Ocular Hypertension
Interventions: ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR; Drug
Lead sponsor: Envisia Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more

Conditions: Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Glaucoma, Open-Angle, Glaucoma
Interventions: iStent Inject Implantation; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Phoenix, Arizona • Torrance, California • Dallas, Texas

Conditions: Intraocular Pressure
Interventions: BOL-303259-X, Latanoprost; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma, Open-Angle
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Mankind Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Culver City, California • La Jolla, California • Los Angeles, California + 35 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

Safety and IOP-Lowering Effects of WB007

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

Pigment Dispersion Syndrome With and Without Glaucoma

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

The Heidelberg Engineering ANTERION Anterior Segment Metrics Precision and Agreement Study

A Trial of Hydrus Microstent Versus Goniotomy

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Excimer Laser Trabeculostomy Glaucoma Treatment Study

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma

iStent Inject New Enrollment Post-Approval Study

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution